Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Luminex, HTG Molecular Diagnostics, Interpace Diagnostics, and More

NEW YORK (360Dx) – Luminex said this week that it has reached an agreement whereby Laboratory Corporation of America is extending its commitment to the Luminex Cystic Fibrosis product line through Dec. 31, 2019. LabCorp would, therefore, maintain at least its current volume of CF testing with Luminex through 2019, Luminex said.

In a separate announcement, Luminex said that its board of directors declared a cash dividend for the third quarter of 2017 of $.06 per share of common stock payable on Oct. 13 to stockholders of record at the close of business on Sept. 22.

HTG Molecular Diagnostics said this week that it expects to complete and file a fourth and final module related to its submission to the US Food and Drug Administration for premarket approval of its HTG EdgeSeq ALKPlus Assay

The in vitro diagnostic assay measures and analyzes mRNA ALK gene rearrangements in lung tumor specimens from patients previously diagnosed with non-small cell lung cancer.

The firm already submitted the first three modules for FDA review, and it intends to launch the assay in the US when it receives premarket approval.

HTG CEO TJ Johnson said in a statement, “Following collaborative discussions with FDA, we have finalized plans to conduct a method comparison study needed to complete and file the fourth and final module."

He said the firm anticipates completing this study in the first quarter of 2018 and submitting the final PMA module in the second quarter of 2018."

Interpace Diagnostics said this week that the American Medical Association has assigned a new, discreet CPT code to facilitate reimbursement of its ThyraMir miRNA-based molecular test for indeterminate thyroid nodules. The firm received the new code, 0018U, following a formal review of its submission. The unique code for ThyraMir will simplify and expedite the process for Interpace in submitting claims and securing reimbursement, the firm said.

Danaher’s board of directors approved a regular quarterly dividend of $.14 per share, payable on Oct. 27 to shareholders of record on Sept. 29.

Abbott declared a quarterly common dividend of $.265 per share, payable Nov. 15 to shareholders of record at the close of business on Oct. 13.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the 360Dx site.